Gujarat Themis Biosyn approves ₹335 crore preferential share allotment
- Gujarat Themis Biosyn board approves preferential allotment of 82.11 lakh equity shares
- Issue priced at ₹408 per share, raising up to ₹335 crore in total
- Promoter group entity Pharmaceutical Business Group (India) Ltd takes largest stake of ₹250 crore
- Four non-promoter investors include Special Situation India Fund and ISAF III Onshore Fund
- Transaction requires shareholder and stock exchange approvals before finalisation
*this image is generated using AI for illustrative purposes only.
Gujarat Themis Biosyn board has approved the preferential allotment of 82.11 lakh shares at ₹408 per share, aggregating to ₹335 crore. The move aims to raise capital through a private placement involving five proposed allottees.
Share issuance details
The board-approved share issuance represents a structured capital-raising exercise by Gujarat Themis Biosyn. The following table summarises the key parameters of the proposed issuance:
| Parameter | Details |
|---|---|
| Number of shares | 82.11 lakh |
| Issue price per share | ₹408 |
| Total issue size | ₹335 crore |
Proposed allottees
The preferential issue is structured as a private placement under Section 42 and 62 of the Companies Act 2013. The board meeting held on September 1, 2026, approved the allotment to five specific investors. Pharmaceutical Business Group (India) Limited, part of the promoter group, is the largest recipient.
| Investor Category | Name of Allottee | Shares (No.) | Amount (₹) |
|---|---|---|---|
| Promoter Group | Pharmaceutical Business Group (India) Limited | 61,27,453 | 250,00,00,824 |
| Non-Promoter | Yusuf Khwaja Hamied | 2,45,100 | 10,00,00,800 |
| Non-Promoter | Special Situation India Fund | 4,59,558 | 18,74,99,664 |
| Non-Promoter | India Special Assets Fund III | 6,83,823 | 27,89,99,784 |
| Non-Promoter | ISAF III Onshore Fund | 6,94,852 | 28,34,99,616 |
Investors other than the promoter group entity are classified as non-promoter/non-promoter group allottees. The total number of investors capped at five aligns with regulatory limits for private placements.
Regulatory approvals pending
The board's approval marks a formal step in the company's capital mobilisation process. The transaction remains subject to shareholder approval and stock exchange clearances. Further details regarding the allotment timeline and final regulatory filings are subject to disclosures as and when made available.
Historical Stock Returns for Gujarat Themis Biosyn
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.65% | -5.84% | -5.70% | +53.93% | -4.33% | +59.20% |
How will the ₹335 crore capital infusion impact Gujarat Themis Biosyn's debt-to-equity ratio and overall liquidity position?
What specific strategic initiatives or capacity expansions is the company planning to fund with this private placement?
Will the significant stake acquisition by the promoter group entity lead to any changes in corporate governance or board composition?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
